MIV-150 is a nonnucleoside inhibitor of reverse transcriptase (NNRT). MIV-150 also blocking HIV-1 and HIV-2 infections (EC50<1 nM against HIV-1/HIV-2MN).

HIV-2:<1 nM (EC50), HIV-1:<1 nM (EC50)

MIV-150 demonstrates potent antiviral efficacy by inactivating free HIV virus with an EC50 of 0.004 μg/mL (or 0.01 μM), showcasing its high effectiveness against HIV, including strains resistant to other marketed antiretrovirals like Nevirapine, Delavirdine, and Efavirenz. Remarkably, resistance to MIV-150 develops slower compared to other anti-HIV drugs, as evident from in vitro studies where resistance to Nevirapine and Delavirdine emerged within 4 to 5 weeks, whereas resistance to MIV-150 took up to 45 weeks. Additionally, MIV-150's ability to protect target cells from infection was demonstrated through a syncytial assay, revealing an EC50 against HIV-1MN in CEM.SS cells below 1 nM, aligning with Medivir's findings.